While compounds such as bortezomib (FDA-approved for multiple myeloma) and Fingolimod (FDA-approved for multiple sclerosis) have shown potential to modulate PP2A or CIP2A activity in preclinical studies, their use specifically for targeting CIP2A in cancer remains experimental. This evidence concerns the gene CIP2A and cancer.